Hikma appoints new President of Injectables business

London, 9 August 2023 – Hikma Pharmaceuticals PLC and its subsidiaries (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, announce that Dr. Bill Larkins has been appointed President of its Injectables business, effective 1 September 2023. Bill will be based in the US and report to Riad Mishlawi in his new role as Hikma’s Chief Executive Officer.

Press Release Leadership 8 August 2023

Bill has extensive experience in the sterile injectable generic market. He was previously Chief Executive Officer of Custopharm, which was acquired by Hikma in 2022 and has since been Hikma´s Senior Vice President, R&D, Injectables.

During his career, Bill has held senior leadership roles at leading injectable pharmaceutical companies including Bedford Laboratories and ESI Lederle/Baxter. He also played a significant role at Schein Pharmaceuticals’ Steris Laboratories in Phoenix and at Amylin Pharmaceuticals, where he worked on the development of complex injectable medicines.

Commenting on the appointment, Riad Mishlawi, President of Injectables / CEO-elect said: "Bill's exceptional leadership skills, vast expertise, and successful track record make him the ideal person to lead our Injectables team. Over the next few years, we have a tremendous opportunity to further expand Hikma’s position as a market-leading manufacturer and supplier of generic injectable medicines. I look forward to working with Bill in his new role.”

Dr. Bill Larkins added: "This is a very exciting opportunity for me to lead a highly talented team, who have been growing and developing this business so successfully over the years. I am confident that we can continue to leverage our differentiated R&D pipeline, capacity expansion projects and new businesses to further enhance our position as one of the leading providers of injectable medicines across our geographies.”

Press release

This is the summary

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.